Trial Profile
Prospective study investigating role of phosphoinositide 3-kinase (PI3K) pathway activation in human epidermal growth factor receptor 2 (HER2)-targeted therapy in advanced gastric cancer patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer
- Focus Pharmacodynamics
- 05 Dec 2015 New trial record